{"id":9305,"date":"2024-01-29T20:29:00","date_gmt":"2024-01-29T12:29:00","guid":{"rendered":"https:\/\/flcube.com\/?p=9305"},"modified":"2024-10-24T20:31:25","modified_gmt":"2024-10-24T12:31:25","slug":"formosa-pharmaceuticals-strikes-licensing-deal-with-cristalia-for-ocular-surgery-pain-treatment-in-brazil","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=9305","title":{"rendered":"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil"},"content":{"rendered":"\n

Taiwan-based Formosa Pharmaceuticals (TPE: 6838<\/a>) has announced the signing of a licensing agreement with Brazil-based Crist\u00e1lia Produtos Quimicos Farmaceuticos Ltda. According to the agreement, Formosa will grant Crist\u00e1lia the commercialization rights for its product candidate APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil, which is being developed as a potential treatment for pain following ocular surgery. Financial details of the deal were not disclosed.<\/p>\n\n\n\n

APP13007 contains the active ingredient clobetasol propionate, a corticosteroid derived from Formosa’s proprietary APNT nanoparticle formulation platform. This technology allows for a dosing regimen of twice daily for 14 days. The product candidate, currently in Phase III, has demonstrated rapid and sustained relief of inflammation and pain, showing clinical superiority over its matching placebo (p<0.001). The US Food and Drug Administration (FDA) is anticipated to complete its regulatory review for the molecule in March 2024.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1419,44,1418],"class_list":["post-9305","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-formosa-pharmaceuticals","tag-ophthalmology","tag-tpe-6838"],"yoast_head":"\nFormosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based Crist\u00e1lia Produtos Quimicos Farmaceuticos Ltda. According to the agreement, Formosa will grant Crist\u00e1lia the commercialization rights for its product candidate APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil, which is being developed as a potential treatment for pain following ocular surgery. Financial details of the deal were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=9305\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=9305\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-29T12:29:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-24T12:31:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9305#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9305\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil\",\"datePublished\":\"2024-01-29T12:29:00+00:00\",\"dateModified\":\"2024-10-24T12:31:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9305\"},\"wordCount\":157,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Formosa Pharmaceuticals\",\"Ophthalmology\",\"TPE: 6838\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9305#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9305\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=9305\",\"name\":\"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-01-29T12:29:00+00:00\",\"dateModified\":\"2024-10-24T12:31:25+00:00\",\"description\":\"Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based Crist\u00e1lia Produtos Quimicos Farmaceuticos Ltda. According to the agreement, Formosa will grant Crist\u00e1lia the commercialization rights for its product candidate APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil, which is being developed as a potential treatment for pain following ocular surgery. Financial details of the deal were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9305#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=9305\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=9305#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil - Insight, China's Pharmaceutical Industry","description":"Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based Crist\u00e1lia Produtos Quimicos Farmaceuticos Ltda. According to the agreement, Formosa will grant Crist\u00e1lia the commercialization rights for its product candidate APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil, which is being developed as a potential treatment for pain following ocular surgery. Financial details of the deal were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=9305","og_locale":"en_US","og_type":"article","og_title":"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=9305","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-01-29T12:29:00+00:00","article_modified_time":"2024-10-24T12:31:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=9305#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=9305"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil","datePublished":"2024-01-29T12:29:00+00:00","dateModified":"2024-10-24T12:31:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=9305"},"wordCount":157,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Formosa Pharmaceuticals","Ophthalmology","TPE: 6838"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=9305#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=9305","url":"https:\/\/flcube.com\/?p=9305","name":"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-01-29T12:29:00+00:00","dateModified":"2024-10-24T12:31:25+00:00","description":"Taiwan-based Formosa Pharmaceuticals (TPE: 6838) has announced the signing of a licensing agreement with Brazil-based Crist\u00e1lia Produtos Quimicos Farmaceuticos Ltda. According to the agreement, Formosa will grant Crist\u00e1lia the commercialization rights for its product candidate APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil, which is being developed as a potential treatment for pain following ocular surgery. Financial details of the deal were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=9305#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=9305"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=9305#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Formosa Pharmaceuticals Strikes Licensing Deal with Crist\u00e1lia for Ocular Surgery Pain Treatment in Brazil"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9305"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9305\/revisions"}],"predecessor-version":[{"id":9306,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/9305\/revisions\/9306"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}